U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28O5
Molecular Weight 360.4448
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALDOSTERONE

SMILES

[H][C@@]12CC[C@H](C(=O)CO)[C@]1(C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C)C=O

InChI

InChIKey=PQSUYGKTWSAVDQ-ZVIOFETBSA-N
InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H28O5
Molecular Weight 360.4448
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Aldosterone is a hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Recent findings have shown that the physiological functions of the hormone aldosterone go far beyond its well-known role in blood-pressure regulation and salt/water homeostasis. Aldosterone is for example involved in the regulation of inflammation, and also binds directly to mineralocorticoid receptors in specific brain regions. At the late distal tubule and collecting duct, aldosterone has two main actions: 1) aldosterone acts on mineralocorticoid receptors (MR) on principal cells in the distal tubule of the kidney nephron, increasing the permeability of their apical (luminal) membrane to potassium and sodium and activates their basolateral Na+/K+ pumps, stimulating ATP hydrolysis leading to phosphorylation of the pump and a conformational change in the pump exposes the Na+ ions to the outside. The phosphorylated form of the pump has a low affinity for Na+ ions, hence reabsorbing sodium (Na+) ions and water into the blood, and secreting potassium (K+) ions into the urine; 2) aldosterone stimulates H+ secretion by intercalated cells in the collecting duct, regulating plasma bicarbonate (HCO3−) levels and its acid/base balance; and 3) aldosterone may act on the central nervous system via the posterior pituitary gland to release vasopressin (ADH) which serves to conserve water by direct actions on renal tubular resorption.

CNS Activity

Curator's Comment: Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder in rodent models.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.8 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
83.6%
ALDOSTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
83%
ALDOSTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
60%
ALDOSTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg single, intravenous
Highest studied dose
Dose: 3 mg
Route: intravenous
Route: single
Dose: 3 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
6 mg 3 times / day multiple, intramuscular
Highest studied dose
Dose: 6 mg, 3 times / day
Route: intramuscular
Route: multiple
Dose: 6 mg, 3 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Metabolic alkalosis.
2001-04
Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency.
2001-04
Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland.
2001-04
Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes.
2001-04
Local inhibition of nitric oxide temporarily stimulates aldosterone secretion in conscious sheep in vivo.
2001-04
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
2001-04
The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action.
2001-04
Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor.
2001-04
Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action.
2001-04
Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK.
2001-04
Diagnosis and management of congenital adrenal hyperplasia: clinical, molecular and prenatal aspects.
2001-03-13
Effect of therapeutic ultrasound on partition and diffusion coefficients in human stratum corneum.
2001-03-12
Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.
2001-03
Nesiritide for the treatment of decompensated heart failure.
2001-03
Effect of chronic oral administration of a low dose of captopril on sodium appetite of hypothyroid rats. Influence of aldosterone treatment.
2001-03
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens.
2001-03
Modulation of transalveolar fluid absorption by endogenous aldosterone in adult rats.
2001-03
Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.
2001-03
Adverse cardiac effects of salt with fludrocortisone in hypertension.
2001-03
Arterial pressure, left ventricular mass, and aldosterone in essential hypertension.
2001-03
Water metabolism disturbances at different stages of primary thyroid failure.
2001-03
Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers.
2001-03
A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
2001-03
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
2001-03
Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases.
2001-03
Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism.
2001-03
Type 1 aldosterone synthase deficiency presenting in a middle-aged man.
2001-03
Approach to the patient with hypertension, unexplained hypokalemia, and metabolic alkalosis.
2001-03
Salt intake and body fluid volumes: have we learned all there is to know?
2001-03
Two sporadic cases of Liddle's syndrome caused by De novo ENaC mutations.
2001-03
Inhibition of aldosterone production in rat adrenal mitochondria by 18-ethynyl-11-deoxycorticosterone: a simple model for kinetic interpretation of mechanism-based inhibitors.
2001-03
The release of antidiuretic hormone is appropriate in response to hypovolemia and/or sodium administration in children with severe head injury: a trial of lactated Ringer's solution versus hypertonic saline.
2001-03
Non-genomic actions of aldosterone: role in hypertension.
2001-03
Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation.
2001-02-28
Molecular mechanisms of human hypertension.
2001-02-23
Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture.
2001-02-15
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
2001-02-03
Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. A pilot study.
2001-02
Volume-induced natriuresis in healthy women: renal metabolism of prostacyclin and thromboxane, and physiological role of prostanoids.
2001-02
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion.
2001-02
Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension.
2001-02
Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
2001-02
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
2001-02
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic.
2001-02
Workshop: mechanisms and cardiovascular damage in hypertension.
2001-02
Effect of furosemide on renal excretion of oxypurinol and purine bases.
2001-02
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
2001-02
Renal function, sodium and water homeostasis in patients with idiopathic extrahepatic portal vein thrombosis compared with normal healthy controls.
2001-01
Tackling polycystic ovary syndrome.
2001-01
Preformulation experiences and in vitro model studies with spironolactone-containing suppositories.
2001-01
Patents

Sample Use Guides

Horses: Aldosterone was injected intravenously for 6 h at 20-min intervals (total 5.4 ug/kg body wt).
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: Cultured neonatal rat ventricular cardiomyocytes were stimulated in vitro with 1 umol/L aldosterone for 24 h. Aldosterone modulates the expression of cardiac voltage-operated Ca2+ channels and accelerates beating in cultured neonatal rat ventricular myocytes. v
Aldosterone within the concentration range of 0.01-1.0 umol/L stimulates the proliferation and osteogenic gene expressions and enhances α-ENaC gene expression in rat osteoblasts in vitro, suggesting the possibility that ENaC participates in aldosterone-mediated regulation of osteoblast functions.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:50:01 GMT 2025
Edited
by admin
on Mon Mar 31 17:50:01 GMT 2025
Record UNII
4964P6T9RB
Record Status FAILED
Record Version
  • Download
Name Type Language
ALDOSTERONE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
NSC-73856
Preferred Name English
ALDOSTERONE [MI]
Common Name English
aldosterone [INN]
Common Name English
Aldosterone [WHO-DD]
Common Name English
ALDOSTERONE [MART.]
Common Name English
11.BETA.,21-DIHYDROXYPREGN-4-ENE-3,18,20-TRIONE
Systematic Name English
Classification Tree Code System Code
LOINC 92896-0
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 34231-1
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
NCI_THESAURUS C2324
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 1765-7
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 13482-5
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 30894-0
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 35185-8
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 1762-4
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 25845-9
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
WHO-ATC H02AA01
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 1764-0
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 31992-1
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 41023-3
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 14587-0
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 92897-8
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 35186-6
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 15010-2
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 1763-2
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
CFR 21 CFR 862.1045
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
WHO-VATC QH02AA01
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 14586-2
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
LOINC 44295-4
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
Code System Code Type Description
CAS
52-39-1
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
EPA CompTox
DTXSID7022419
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
DAILYMED
4964P6T9RB
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
EVMPD
SUB05306MIG
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
PUBCHEM
5839
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
SMS_ID
100000087869
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
NCI_THESAURUS
C219
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
CAS
6251-69-0
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
ALTERNATIVE
FDA UNII
4964P6T9RB
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
ChEMBL
CHEMBL273453
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
MERCK INDEX
m1488
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY Merck Index
CHEBI
30834
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
DRUG CENTRAL
111
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
NSC
73856
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
CHEBI
27584
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
MESH
D000450
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
WIKIPEDIA
ALDOSTERONE
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
DRUG BANK
DB04630
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
INN
483
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-139-9
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY
RXCUI
1312358
Created by admin on Mon Mar 31 17:50:02 GMT 2025 , Edited by admin on Mon Mar 31 17:50:02 GMT 2025
PRIMARY RxNorm
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
A clear hierarchy of antinatriuretic activity, aldosterone > 5.alpha.-DHA > 3.alpha.,5.alpha-THA > 3.alpha.,5.beta.-THA > 3.beta.,5.alpha.-THA > 5.beta.-DHA > 3.beta.,5.beta.-THA was observed
METABOLITE LESS ACTIVE -> PARENT
A clear hierarchy of antinatriuretic activity, aldosterone > 5.alpha.-DHA > 3.alpha.,5.alpha-THA > 3.alpha.,5.beta.-THA > 3.beta.,5.alpha.-THA > 5.beta.-DHA > 3.beta.,5.beta.-THA was observed
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC